Identifying Drug Effects via Pathway Alterations using an Integer Linear Programming Optimization Formulation on Phosphoproteomic Data
暂无分享,去创建一个
Julio Saez-Rodriguez | Alexander Mitsos | Leonidas G. Alexopoulos | Ioannis N. Melas | Aikaterini D. Chairakaki | Paraskeuas Siminelakis | A. Mitsos | J. Sáez-Rodríguez | L. Alexopoulos | I. Melas | A. Chairakaki | Paraskeuas Siminelakis
[1] M. Gerstein,et al. A Bayesian Networks Approach for Predicting Protein-Protein Interactions from Genomic Data , 2003, Science.
[2] S. Schreiber,et al. Printing proteins as microarrays for high-throughput function determination. , 2000, Science.
[3] P. Shannon,et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.
[4] E. Butcher,et al. Can cell systems biology rescue drug discovery? , 2007, Ernst Schering Research Foundation workshop.
[5] David Kendrick,et al. GAMS, a user's guide , 1988, SGNM.
[6] V. Grantcharova,et al. Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor–PI3K Axis , 2009, Science Signaling.
[7] Mindy I. Davis,et al. A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.
[8] John G. Albeck,et al. Cue-Signal-Response Analysis of TNF-Induced Apoptosis by Partial Least Squares Regression of Dynamic Multivariate Data , 2004, J. Comput. Biol..
[9] S. L. Wong,et al. Towards a proteome-scale map of the human protein–protein interaction network , 2005, Nature.
[10] Lili X. Peng,et al. A High-throughput Quantitative Multiplex Kinase Assay for Monitoring Information Flow in Signaling Networks , 2003, Molecular & Cellular Proteomics.
[11] P. Bork,et al. Literature mining for the biologist: from information retrieval to biological discovery , 2006, Nature Reviews Genetics.
[12] S. Hall,et al. Chemoproteomics-driven drug discovery: addressing high attrition rates. , 2006, Drug discovery today.
[13] M. Chaparro,et al. Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents , 2008, Alimentary pharmacology & therapeutics.
[14] Paul I. Barton,et al. Process-wide integration of solvent mixtures , 1999 .
[15] Diego di Bernardo,et al. Identifying Network of Drug Mode of Action by Gene Expression Profiling , 2009, J. Comput. Biol..
[16] J. McCubrey,et al. BAY-43-9006 Bayer/Onyx. , 2003, Current opinion in investigational drugs.
[17] G. Siemeister,et al. Off‐Target Decoding of a Multitarget Kinase Inhibitor by Chemical Proteomics , 2009, Chembiochem : a European journal of chemical biology.
[18] Min Wu,et al. Fishing for targets: novel approaches using small molecule baits. , 2004, Drug discovery today. Technologies.
[19] Steven A Carr,et al. Identifying the proteins to which small-molecule probes and drugs bind in cells , 2009, Proceedings of the National Academy of Sciences.
[20] Hiroaki Kitano,et al. Foundations of systems biology , 2001 .
[21] Bernhard Kuster,et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors , 2007, Nature Biotechnology.
[22] Steffen Klamt,et al. The Logic of EGFR/ErbB Signaling: Theoretical Properties and Analysis of High-Throughput Data , 2009, PLoS Comput. Biol..
[23] Julio Saez-Rodriguez,et al. Fuzzy Logic Analysis of Kinase Pathway Crosstalk in TNF/EGF/Insulin-Induced Signaling , 2007, PLoS Comput. Biol..
[24] Masao Nagasaki,et al. Foundations of Systems Biology - Using Cell Illustrator® and Pathway Databases , 2009, Computational Biology.
[25] L. Wodicka,et al. A small molecule–kinase interaction map for clinical kinase inhibitors , 2005, Nature Biotechnology.
[26] Ioannis Xenarios,et al. A method for the generation of standardized qualitative dynamical systems of regulatory networks , 2005, Theoretical Biology and Medical Modelling.
[27] K. Sachs,et al. Causal Protein-Signaling Networks Derived from Multiparameter Single-Cell Data , 2005, Science.
[28] C. Sander,et al. Models from experiments: combinatorial drug perturbations of cancer cells , 2008, Molecular systems biology.
[29] D. Auclair,et al. BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.
[30] Paul A Clemons,et al. The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.
[31] Hong Ma,et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways , 2002, Oncogene.
[32] S. Brahmachari,et al. Boolean network analysis of a neurotransmitter signaling pathway. , 2007, Journal of theoretical biology.
[33] Julio Saez-Rodriguez,et al. Flexible informatics for linking experimental data to mathematical models via DataRail , 2008, Bioinform..
[34] Klaus Truemper,et al. Logic Integer Programming Models for Signaling Networks , 2008, J. Comput. Biol..
[35] Steffen Klamt,et al. Structural and functional analysis of cellular networks with CellNetAnalyzer , 2007, BMC Systems Biology.
[36] Alexander Mitsos,et al. Optimal automatic reaction and species elimination in kinetic mechanisms , 2008 .
[37] Arthur W. Westerberg,et al. Optimization for design problems having more than one objective , 1983 .
[38] M. Mann,et al. Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. , 2008, Molecular cell.
[39] D. Lauffenburger,et al. A Compendium of Signals and Responses Triggered by Prodeath and Prosurvival Cytokines*S , 2005, Molecular & Cellular Proteomics.
[40] D. Lauffenburger,et al. Discrete logic modelling as a means to link protein signalling networks with functional analysis of mammalian signal transduction , 2009, Molecular systems biology.
[41] S. Kauffman. Metabolic stability and epigenesis in randomly constructed genetic nets. , 1969, Journal of theoretical biology.
[42] Krystal J Alligood,et al. A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib) , 2004, Cancer Research.
[43] J. Collins,et al. Chemogenomic profiling on a genome-wide scale using reverse-engineered gene networks , 2005, Nature Biotechnology.
[44] Mark Robinson,et al. A short-term operational planning model for natural gas production systems† , 2008 .
[45] Julio Saez-Rodriguez,et al. High‐Throughput Protein‐Based Technologies and Computational Models for Drug Development, Efficacy, and Toxicity , 2008 .
[46] T. Gardner,et al. The mode-of-action by network identification (MNI) algorithm: a network biology approach for molecular target identification , 2006, Nature Protocols.
[47] Steffen Klamt,et al. Hypergraphs and Cellular Networks , 2009, PLoS Comput. Biol..
[48] P Norman,et al. OSI-774 OSI Pharmaceuticals. , 2001, Current opinion in investigational drugs.
[49] Kevan M Shokat,et al. Features of selective kinase inhibitors. , 2005, Chemistry & biology.
[50] P. Zarrinkar,et al. High-throughput kinase profiling as a platform for drug discovery , 2008, Nature Reviews Drug Discovery.